Analysts Set Haleon plc (LON:HLN) Target Price at GBX 395.67

Shares of Haleon plc (LON:HLN) have received a consensus rating of “Hold” from the six research firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is GBX 399.

A number of equities analysts have weighed in on HLN shares. Berenberg Bank increased their price target on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Jefferies Financial Group reissued a “buy” rating and set a GBX 400 price target on shares of Haleon in a research report on Friday, July 31st. JPMorgan Chase & Co. cut their price objective on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a report on Thursday, June 25th. Royal Bank Of Canada boosted their target price on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Haleon from GBX 325 to GBX 335 and gave the company a “sell” rating in a report on Friday, July 31st.

Haleon Stock Performance

Haleon stock opened at GBX 355.60 on Monday. The stock has a fifty day moving average price of GBX 355.50 and a 200 day moving average price of GBX 362.69. Haleon has a 52 week low of GBX 317.80 and a 52 week high of GBX 416.10. The firm has a market capitalization of £31.32 billion, a P/E ratio of 19.65, a PEG ratio of 1.49 and a beta of 0.24. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38.

Haleon (LON:HLN) last posted its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. Equities research analysts anticipate that Haleon will post 19.5033282 earnings per share for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.